

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Bakulesh M. Khamar et al.

Examiner: Rodney P. Swartz

Application Serial No.: 10/565,211

Group Art Unit: 1645

Filing Date: October 30, 2006

Priority Application: PCT/IB03/00860 filed March 11, 2003

Indian application no. 247/MUM/2002 filed 13 March 2002

For: PROCESS FOR MANUFACTURING PHARMACEUTICAL COMPOSITION  
COMPRISES OF MYCOBACTERIUM W IN THE TREATMENT OF ASTHMA  
(OBSTRUCTIVE LUNG DISEASE)

CERTIFICATION UNDER 37 C.F.R. 1.373(B) SUPPLEMENTING A POWER OF  
ATTORNEY FILED IN THE ABOVE APPLICATION

The undersigned, Bakulesh M. Khamar (<sup>Mr</sup>~~Ph.D.~~), states:

1. I am the Executive Director of Cadila Pharmaceuticals Limited ("Cadila") of India, assignee of the above cited application, and duly empowered to act for it in patent application matters. I am also a named co-applicant/co-inventor of the above cited application.

2. The U.S. patent application is a 35 U.S.C. § 371 national phase entry of the PCT application cited above and indicating Applicants as Cadila for all countries (except the United States) and the inventions for the U.S. a pattern of many U.S. applications by Cadila. That pattern also includes recording assignments of individual inventors and the pattern was followed in this case with an assignment recorded at Reel 021021 Frame 0548, recorded by the U.S. Patent & Trademark Office Assignment Branch on May 30, 2008.

Given under pains and penalties of perjury of U.S. law.

Dated: September <sup>6<sup>th</sup></sup>, 2010

<sup>(Chaman)</sup>  
Bakulesh M. Khamar  
Executive Director  
Cadila Pharmaceuticals Limited

Enclosure: Power of Attorney